HRP20161666T1 - Upotreba pidotimoda u liječenju psorijaze - Google Patents
Upotreba pidotimoda u liječenju psorijaze Download PDFInfo
- Publication number
- HRP20161666T1 HRP20161666T1 HRP20161666TT HRP20161666T HRP20161666T1 HR P20161666 T1 HRP20161666 T1 HR P20161666T1 HR P20161666T T HRP20161666T T HR P20161666TT HR P20161666 T HRP20161666 T HR P20161666T HR P20161666 T1 HRP20161666 T1 HR P20161666T1
- Authority
- HR
- Croatia
- Prior art keywords
- pidotimod
- intended
- acceptable salt
- physiologically acceptable
- accordance
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title claims 21
- 229960001163 pidotimod Drugs 0.000 title claims 21
- 201000004681 Psoriasis Diseases 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012669 liquid formulation Substances 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims 1
- 229960005339 acitretin Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960002916 adapalene Drugs 0.000 claims 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 1
- 229960002459 alefacept Drugs 0.000 claims 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims 1
- 229960002882 calcipotriol Drugs 0.000 claims 1
- 229960005084 calcitriol Drugs 0.000 claims 1
- 235000020964 calcitriol Nutrition 0.000 claims 1
- 239000011612 calcitriol Substances 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960002199 etretinate Drugs 0.000 claims 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960005280 isotretinoin Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- -1 preferably retinoids Chemical compound 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 229960004907 tacalcitol Drugs 0.000 claims 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229960000565 tazarotene Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (16)
1. Pidotimod, ili njegova fiziološki prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
2. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedena psorijaza psorijaza kože, psorijaza noktiju ili psorijatični artritis.
3. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje na čovjeku.
4. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje sistemno.
5. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se primjenjuje u obliku čvrste ili tekuće formulacije.
6. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što je navedena čvrsta formulacija tableta, filmom obložena tableta, kapsula, dražeja ili vrećica.
7. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što je navedena tekuća formulacija otopina ili suspenzija.
8. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što navedena čvrsta formulacija ima tež./tež. koncentraciju pidotimoda od 50% do 90%, poželjnije od 65% do 80%, najpoželjnije od 70% do 75%.
9. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što navedena tekuća formulacija ima tež./tež. koncentraciju pidotimoda od 0,5% do 20%, poželjnije od 1% do 10%, najpoželjnije od 2% do 8%.
10. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što navedena formulacija ima sadržaj pidotimoda, ili njegove soli, od 10 do 1000 mg po pojedinačnoj dozi, po mogućnosti od 50 do 800 mg po pojedinačnoj dozi.
11. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje topikalno.
12. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što se primjenjuje u obliku polučvrste ili tekuće formulacije.
13. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je polučvrsta formulacija krema, gel, mast ili emulzija.
14. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je navedena tekuća formulacija otopina ili suspenzija.
15. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što navedena formulacija ima tež./tež. koncentraciju pidotimoda, ili njegove soli, od 0,1% do 20%, po mogućnosti od 1% do 15%, poželjnije od 5% do 10%.
16. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se primjenjuje u kombinaciji ili vremenski blizu najmanje jednom dodatnom aktivnom sastojku, gdje se navedeni najmanje jedan dodatni aktivni sastojak bira između imunosupresivnih sredstava, po mogućnosti metotreksata, azatioprina, ciklosporina, fumarne kiseline, takrolimusa ili pimekrolimusa i kortikosteroida, vitamina D i njegovih analoga, po mogućnosti kalcitriola, kalcipotriola i takalcitola, spojeva srodnih vitaminu A, po mogućnosti retinoida, tretinoina, izotretinoina, etretinata, acitretina, tazarotena, beksarotena i adapalena, bioloških tvari, po mogućnosti alefacepta, etanercepta, te monoklonskih protutijela adalimumaba, infliksimaba, ustekinumaba.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12812221.5A EP2934521B1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
| PCT/EP2012/076088 WO2014094840A1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161666T1 true HRP20161666T1 (hr) | 2017-01-27 |
Family
ID=47520054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161666TT HRP20161666T1 (hr) | 2012-12-19 | 2016-12-07 | Upotreba pidotimoda u liječenju psorijaze |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (hr) |
| EP (1) | EP2934521B1 (hr) |
| JP (1) | JP6051315B2 (hr) |
| KR (1) | KR20150095773A (hr) |
| CN (1) | CN104869994B (hr) |
| AR (1) | AR094027A1 (hr) |
| AU (1) | AU2012396942A1 (hr) |
| BR (1) | BR112015011391A2 (hr) |
| CA (1) | CA2887878A1 (hr) |
| CY (1) | CY1118645T1 (hr) |
| DK (1) | DK2934521T3 (hr) |
| EA (1) | EA201591185A1 (hr) |
| ES (1) | ES2617235T3 (hr) |
| HK (1) | HK1210937A1 (hr) |
| HR (1) | HRP20161666T1 (hr) |
| HU (1) | HUE031846T2 (hr) |
| IL (1) | IL239429A0 (hr) |
| LT (1) | LT2934521T (hr) |
| MA (1) | MA38155B1 (hr) |
| ME (1) | ME02560B (hr) |
| MX (1) | MX2015008104A (hr) |
| PH (1) | PH12015501210A1 (hr) |
| PL (1) | PL2934521T3 (hr) |
| PT (1) | PT2934521T (hr) |
| RS (1) | RS55436B1 (hr) |
| SG (1) | SG11201503270UA (hr) |
| SI (1) | SI2934521T1 (hr) |
| SM (1) | SMT201700072B (hr) |
| TN (1) | TN2015000142A1 (hr) |
| WO (1) | WO2014094840A1 (hr) |
| ZA (1) | ZA201502573B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (en) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod for use in the treatment of inflammation-associated diseases |
| KR20180128471A (ko) * | 2016-03-29 | 2018-12-03 | 얀센 바이오테크 인코포레이티드 | 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료 |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase |
-
2012
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/en active Active
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 CA CA2887878A patent/CA2887878A1/en not_active Abandoned
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/en active Application Filing
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/me unknown
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Application Discontinuation
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
- 2015-11-26 HK HK15111635.1A patent/HK1210937A1/xx unknown
-
2016
- 2016-12-07 HR HRP20161666TT patent/HRP20161666T1/hr unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maier et al. | Magnesium and inflammation: Advances and perspectives | |
| HRP20161666T1 (hr) | Upotreba pidotimoda u liječenju psorijaze | |
| ES2541488T3 (es) | Espuma farmacéutica penetrante | |
| CN105209036B (zh) | 氧杂双环庚烷和氧杂双环庚烯的配制品 | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| UA114615C2 (uk) | Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти | |
| JP2013100317A5 (hr) | ||
| JP2018526325A5 (hr) | ||
| HRP20211377T1 (hr) | Prirodne kombinirane hormonske supstitucijske formulacije i terapije | |
| HRP20160403T1 (hr) | Liječenje lipodistrofije | |
| RU2015131112A (ru) | Липидный предконцентрат катионного фармакологически активного вещества с длительным высвобождением и содержащая его фармацевтическая композиция | |
| BR112016022159B8 (pt) | Pó e método para melhorar a aplicação tópica de um agente de benefício ácido | |
| HRP20191982T1 (hr) | Kombinacijsko liječenje raka | |
| JP2015520235A5 (hr) | ||
| HRP20161667T1 (hr) | Upotreba pidotimoida u liječenju atopičnog dermatitisa | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20120915T1 (hr) | Upotreba kitozana u lijeäśenju upalnih bolesti noktiju | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| CA2963952A1 (en) | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states | |
| NZ702342A (en) | Pharmaceutical formulation | |
| HRP20201844T1 (hr) | Biodostupni poliamini | |
| RU2012137904A (ru) | Дерматологическая, фармацевтическая композиция, пригодная для олигонуклеотидов | |
| JP2016510747A5 (hr) | ||
| BR112014026596A2 (pt) | composição pesticida sinérgica | |
| CA2909995C (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients |